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Healthy volunteers were administered piperacillin i.v. Duodenal aspirates were col-
lected via a custom-made oroenteric catheter; blood and urine also were collected.
Gallbladder ejection fraction (EF) was determined by gamma scintig raphy and phar-





























This methodology can be used to determine reliably the biliary clearance of drugs
that are excreted only marginally into bile. Normalization of biliary clearance for EF




Major challenges in developing an accurate method to
quantify biliary clearance in healthy humans include the
complex anatomy of the human hepatobiliary system, as
well as the intermittent and incomplete expulsion of bile
from the gallbladder. Pharmacological contraction of the
gallbladder has been employed to collect as much bile
stored within the gallbladder as possible [1]. However,
gallbladder response can vary considerably among
human subjects and is influenced by a variety of factors.
The estimated extent of biliary excretion of the drug of
interest may be inaccurately low and intersubject vari-
ability may be exaggerated unless the degree of gall-
bladder contraction is considered.
Recently, we developed a technique to quantify bil-
iary clearance of compounds in humans that couples
gamma scintigraphy with a specially designed oroen-
teric catheter [2]. This catheter is equipped with an
inflatable occlusive balloon that facilitates periodic col-
lection of duodenal fluids and bile. The gallbladder ejec-
tion fraction (EF) is determined by administering a
hepatobiliary imaging agent (Tc-99m mebrofenin) that
allows visualization of the gallbladder before, during
and after pharmacological contraction. Administration
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of a gamma emitter that is excreted into bile also aids
in the identification of bile leakage beyond the occlusive
balloon in the duodenum. The versatility of this
approach was investigated by applying it to piperacillin,
a drug expected to exhibit low biliary clearance. Piper-
acillin is a third-generation, broad-spectrum, penicillin
derivative used in the treatment of intra-abdominal
infections and prophylactically for gastrointestinal and
biliary tract procedures [3].
Additionally, the effect of prolonged intubation on
gallbladder contractility and on the determination of
biliary clearance of drugs was investigated by compar-
ing the recovery of Tc-99m mebrofenin in the present






Three male volunteers (23–40 years of age) within 20%
of ideal body weight completed the study. The Clinical
Research Advisory Committee and the Committee on
the Protection of the Rights of Human Subjects at the
University of North Carolina at Chapel Hill School of
Medicine approved all procedures. Written informed
consent was obtained from all subjects.
Since prolonged fasting can prevent gallbladder con-
traction in response to cholecystokinin-8 (CCK-8)
administration, subjects were given a high-fat caffeine-
free meal 12 h prior to the procedure and a high-fat
snack 5 h later, in order to maintain gallbladder contrac-
tile response. After an overnight fast, a custom-made
oroenteric tube was positioned in the upper duodenum
as previously described [2]. The distal end of the tube
was fitted with a polyethylene balloon, which was
inflated to occlude the intestine during bile collection.
Subjects were administered 2 g of piperacillin (gift of
American Pharmaceutical Partners Inc., Schaumburg,
IL, USA) as a 15-min i.v. infusion and blood samples
were collected at designated times through 600 min. To





; Bracco Diagnostics, Princeton, NJ, USA)
was administered as an i.v. bolus 2 h post piperacillin,
subjects were positioned under a gamma camera (E-
CAM Dual Head Gamma Camera; Siemens Inc., Hoff-
man Estates, IL, USA) and 1-min anterior planar gamma
scintigraphic images of the abdomen were acquired for
4 h. To collect the majority of the bile containing drug
accumulated in the gallbladder, contraction was induced















sion over 30 min) 4 h after piperacillin administration.
If CCK-8 failed to contract the gallbladder, 10–20 ml of
half-milk/half-cream was delivered into the stomach
ports of the catheter to stimulate endogenous CCK secre-
tion by the presence of partially digested proteins and
fats in the small intestine [4]. In one case, orange zest
was used as an olfactory stimulant to promote gallbladder
contraction upon failure of the previously described
methods. Duodenal aspirates were collected for 6 h,
urine and blood were collected for 10 h. Radioactivity
was quantified in blood, bile and urine as previously
described [2]. Piperacillin was quantified in plasma, bile




High-performance liquid chromatography (HPLC-UV)
was used to quantify piperacillin in plasma and urine.
An HP1050 system (Agilent Technologies Inc., Love-













 4.60 mm), the






, detection wavelength 254 nm










. Samples were anal-





pH 5.2/acetonitrile). For plasma, the gradient started at
18% acetonitrile and increased to 25% over 7 min; for
urine, the gradient started at 13% acetonitrile and
increased to 25% over 9 min. Prior to analysis, cefoxitin



















l of ammonium sulphate
saturated solution was added to precipitate proteins.




l of acetonitrile and centrifuga-




 for 10 min), the supernatant was evapo-
rated and reconstituted in sodium acetate. Urine samples
were diluted with mobile phase containing cefoxitin.
Accuracy ranged between 83 and 119%, and the interday




11% for both matrices.
HPLC-MS-MS was used to quantify piperacillin in
bile. Samples were diluted 1 : 7 with methanol contain-











HP1100 system (Agilent) was coupled to an Applied
Biosystems API4000 mass spectrometer with a Tur-
boIonSpray source and controlled by Analyst software
(Foster City, CA, USA). The analytes were eluted with




















. The gradient was held
at 95% water for 0.5 min, then decreased to 10% water
over  2 min  and  held  for  1 min  and  then  returned  to
100% water at 3.5 min, with a total run time of 4 min.
















A gallbladder EF was calculated from anterior planar
scintigraphic images using ESOFT 2.5 software (Sie-
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mens) as described below. GB represents the counts over
the gallbladder region and the time in all formulae refers
to the minutes after piperacillin administration. The




) collected in bile during the
time period used for the EF calculation was normalized
by EF to account for the drug excreted into bile yet



































bile over 4 h was calculated and corrected by EF in order
to compare the recovery obtained in this study with
previous results [2]:
Noncompartmental analysis was used to calculate phar-





(Pharsight, Mountain View, CA, USA). The area under
the plasma concentration–time curves (AUC) was cal-
culated using the linear trapezoidal rule and, where
appropriate, extrapolated to infinity using the slope
obtained from linear regression of the last three to six




























 was 180 min for Tc-99m





































































The overall duration of intubation and fasting time
between the administration of Tc-99m mebrofenin and
CCK-8 in this study was 4 h longer than in the design
adopted previously [2] to account for the longer elimi-
nation half-life of piperacillin. These modifications
appeared to affect gallbladder contractility. All seven
subjects enrolled in these two studies reported intestinal
cramping in response to CCK-8. Three out of four sub-





one of the volunteers enrolled here demonstrated normal
gallbladder contraction by the end of the study [5]. Since
CCK-8 did not completely contract the gallbladder of
subjects A, B or C, these volunteers were administered
10–20 ml half-milk/half-cream at 160 min post Tc-99m
mebrofenin administration in order to prompt endoge-
Piperacillin X X X EFGB bile bile= + ( )0 240 240 360– min – min /











nous CCK release. Subject A demonstrated satisfactory




0.82) following fatty food
(milk/cream) administration, while subjects B and C did
not. Due to complete lack of response to CCK-8 and
half-milk/half-cream, subject C was asked to smell
orange zest 200 min post Tc-99m mebrofenin adminis-
tration in an attempt to stimulate gallbladder discharge.
As seen in Figure 1, the majority of piperacillin recov-
ered in the duodenal aspirates corresponded to the suc-
cessful contraction of the gallbladder and subsequent
bile discharge into the duodenal lumen in all three
subjects.
Piperacillin pharmacokinetics were similar to previ-
ously published data [6]. The mean plasma concentra-
tion–time profile and individual cumulative biliary
excretion plots for subjects A, B and C are presented in
Figure 1 and pharmacokinetic parameters are listed in
Table 1. Piperacillin biliary recovery was minimal, with
the majority of the dose excreted as unchanged drug in
urine. Correction for incomplete contraction of the gall-
bladder decreased intersubject variability in the estimate
of the amount of piperacillin excreted in bile and in the
calculation of the corrected biliary clearance, by
accounting for the amount of piperacillin that would
have been collected if the EF had been complete
(Table 1). Additionally, the calculation of Tc-99m









 14.9%) and comparable to












) – time profile up to 360 min 




 SD). Individual piperacillin cumulative 
biliary recoveries expressed as a percentage of the maximum recovery are 
plotted on the right axis for subjects A (——), B (–.–) and C (---). CCK-8, 
fatty food (milk) and orange zest were administered at 240, 280 and 
320 min post piperacillin administration (arrows)
Time (min)
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mebrofenin dose recovered in bile, corrected for EF, can
be used to calculate the corrected biliary clearance of
this probe for the four subjects enrolled in our previous






















 kg−1  vs.  CLbiliary  12.5 ±
3.6 ml min−1 kg−1), biliary elimination accounts for 93%
of Tc-99m mebrofenin systemic clearance (17.3 ±
1.7 ml min−1 kg−1 [2]).
Discussion
Inconsistent contraction of the gallbladder in healthy
volunteers after CCK-8 administration has not been
reported extensively in the literature, but has been
observed by our group during the development of the
current methodology [7]. The lack of responsiveness to
CCK-8 may be attributed to many factors, including
prolonged fasting or the presence of the tube and
inflated balloon in the duodenum for a prolonged period
of time. It is well documented in animals that the duode-
num is important in maintaining sphincter of Oddi
response to CCK [8]. Thus, it is possible that the pres-
sure exerted by the inflated balloon on the duodenal
walls may have modified the response to CCK-8. Alter-
natively, it is possible that subjects in our study may
have expressed rare polymorphisms or have had down-
regulation of the CCKA/CCK1 receptor on gallbladder
smooth muscle, which would have caused hypomotility
in response to CCK-8 [9]. It is also possible, but
unlikely, that the infusion rate affected subject response
to CCK-8; the CCK-8 infusion rate in this study was
chosen to mimic closely physiological serum CCK pro-
files after a fatty meal and to minimize the adverse
effects of CCK-8 (abdominal cramps, nausea) and vari-
ability in gallbladder contraction [5].
Piperacillin biliary excretion estimates in this study
are consistent with published results [10, 11] and dem-
onstrate that piperacillin is only marginally eliminated
into bile in humans. The correction of the excreted dose
of piperacillin for the gallbladder EF greatly diminished
intersubject variability and yielded estimates for the
fraction of dose excreted into bile similar to previously
reported values in T-tube patients [11]. These results
established that incorporation of the EF factor in the
biliary clearance calculation can provide a method to
account for some of the inherent variability associated
with the determination of this parameter in healthy vol-
unteers.
Some variability in determining the biliary clearance
of drugs by collecting duodenal bile may be associated
with the failure to account for the fraction of the dose
excreted into bile by hepatocytes, but reabsorbed
through the ductal and gallbladder epithelial cells. In
addition, it is not possible to distinguish biliary excre-
tion from duodenal secretion of drugs using this meth-
odology. However, the bile-rich duodenal aspirates are
collected as soon as they are expelled into the intestinal
lumen in order to minimize intestinal reabsorption.
Investigating the mechanisms of biliary clearance of
drugs in healthy volunteers presents a number of chal-
lenges, including the inability to collect liver bile readily
or obtain complete bile collection utilizing non-invasive
techniques. Nevertheless, this study demonstrates that a
combination of tools can be used to obtain a reliable
estimate of the biliary clearance of a drug in healthy
humans.
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Table 1
Summary of individual and mean pharmacokinetic parameters, biliary recovery and urinary recovery of piperacillin and ejection 
fraction for subjects A, B and C
Parameter Subject A Subject B Subject C Mean SD
Administered dose (mg) 1700 1764 1586 1683 90
Biliary recovery (% dose) 0.77 0.32 0.14 0.41 0.32
Urinary recovery (% dose) 72 85 60 72 13
Ejection fraction 0.82 0.28 0.07 0.39 0.39
Recovery of Excreted dose (% dose) 0.87 1.1 1.4 1.1 0.3
CLtotal (ml min−1 kg−1) 3.2 2.5 2.9 2.9 0.3
CLbiliary (ml min−1 kg−1) 0.025 0.008 0.004 0.012 0.011
in vivo CLbiliary (ml min−1 kg−1) 0.028 0.028 0.041 0.032 0.008
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